Table 2.
Clinical trials with single-agent regimens or combinations of melanoma MAPKi and IMMUNOi drugs
| Inhibitor | Gene target | Trials | Drug name | Compound | PubChem | Trade |
|---|---|---|---|---|---|---|
| MAPKi | BRAF | [38, 49–51] | Vemurafenib | PLX4032 | CID: 42611257 | Zelboraf |
| Dabrafenib | GSK2118436 | CID: 44462760 | ||||
| Encorafenib | LGX818 | CID: 50922675 | ||||
| MAPKi | MAP2K7 (MEK) | [39] | Trametinib | GSK-1120212 | CID: 11707110 | |
| Cobimetinib | GDC-0973 | CID: 16222096 | ||||
| MAPKi | Combination of BRAF and MEK inhibition | [40–43, 52–54] | ||||
| IMMUNOi | CTLA4 | [55–59] | Ipilimumab | MDX-010 | SID: 131273201 | |
| Tremelimumab | CP-675206 | SID: 47208308 | ||||
| IMMUNOi | PDCD1 (PD1) | [60] | Nivolumab | MDX-1106 | SID: 135341610 | Opdivo |
| Pembrolizumab | MK-3475 | SID: 187051801 | Keytruda | |||
| IMMUNOi | CD274 (PDL1) | Atezolizumab | 1380723-44-3 | SID: 312642102 | Tecentriq | |
| IMMUNOi | Combination of PDCD1 and CTLA4 blockage | [44–46, 61] |
Current clinical trials utilize small-molecule mitogen-activated protein kinase inhibitors (MAPKi) or humanized antibodies as immune checkpoint inhibitors (IMMUNOi). Molecules are referenced based on their unique PubChem chemical identifier CID or substance identifier SID